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Significant Response 
to Gemcitabine 
Monotherapy in 
Primary Pleural 
Epithelioid 
Angiosarcoma
To the Editor:
Systemic chemotherapy is one 
treatment option for advanced epithe-
lioid angiosarcoma, but no standard reg-
imen has yet been established because 
of the rarity of the disease. We report a 
case of advanced epithelioid angiosar-
coma showing marked response with 
gemcitabine monotherapy.
A 72-year-old man presented 
with a 1-month history of dyspnea 
on exertion. Computed tomography 
revealed a left pleural tumor measur-
ing 6.5 cm and bilateral pleural effu-
sions. Histopathological examination of 
the pleural tumor obtained by biopsies 
under echographic guidance revealed 
neoplastic proliferation characterized 
by nests of highly atypical, large, and 
round to spindle-shaped epithelioid 
cells with abundant eosinophilic cyto-
plasm and hyperchromatic nuclei con-
taining prominent nucleoli. Atypical 
epithelioid cells showed focal areas of 
vascular formation and intracellular 
lumina containing erythrocytes, and 
positive staining for CD31, a vascular 
marker. Advanced epithelioid angiosar-
coma with bilateral malignant pleural 
effusions was diagnosed, and systemic 
chemotherapy was initiated.
Despite treatment using four 
cycles of combination chemotherapy 
with ifosfamide and adriamycin, new 
evidence suggested skin and pulmonary 
metastases. After two cycles of second-
line chemotherapy with carboplatin 
and etoposide, skin lesions enlarged. 
Paclitaxel monotherapy (80 mg/m2 on 
days 1, 8, and 15 every 28 days) was 
administered as a third-line option, but 
cutaneous involvement progressed. As 
the patient suffered from severe cancer 
pain and bleeding from skin metasta-
ses after paclitaxel monotherapy, he 
received oral S-1 with concurrent pal-
liative radiotherapy to the skin lesions, 
which also proved insufficient. Skin 
metastases progressed rapidly (Figs. 1 
and 2A), and the patient underwent fifth-
line chemotherapy with gemcitabine 
(1000 mg/m2 on days 1 and 8, every 
21 days). After six cycles of gemcit-
abine monotherapy, computed tomog-
raphy revealed excellent response with 
marked reduction of skin lesions (Fig. 
2B). As cancer pain and bleeding were 
markedly improved, the patient contin-
ued gemcitabine monotherapy for nine 
cycles over 30 weeks, with good quality 
of life. The patient died 2 years after ini-
tial diagnosis because of serious hem-
orrhage from the tumor.
Epithelioid angiosarcomas are a 
subtype of soft-tissue sarcoma (STS) 
and are extremely rare aggressive 
malignancies of endothelial origin.1 The 
prognosis of unresectable angiosarcoma 
is typically poor. Penel et al.2 reported 
a median time to progression of 4 
months, with median overall survival 
of 8 months. Patients with angiosar-
coma display symptoms attributable 
to a hypocoagulable state.3 The pres-
ent patient suffered bleeding from skin 
metastases. For advanced-stage disease, 
systemic chemotherapy is considered 
a treatment option. As a monotherapy, 
paclitaxel has shown effectiveness 
against advanced-stage angiosarcoma.2 
Gemcitabine has been reported as inac-
tive against advanced STS, providing a 
response rate of only 3.23%.4 However, 
Stacchiotti et al.5 recently reported 
the overall response rate of advanced 
angiosarcoma to gemcitabine was 68%, 
with acceptable levels of toxicity. This 
suggests that gemcitabine could rep-
resent a good option for unresectable 
angiosarcoma, if not other subtypes of 
STS. Although paclitaxel was ineffec-
tive in our case, gemcitabine led to good 
response with noted reduction of the skin 
mass. The patient’s overall condition 
also improved markedly. The favorable 
clinical outcome in this case suggests 
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gemcitabine monotherapy as a promis-
ing therapeutic option for patients with 
unresectable epithelioid angiosarcoma.
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Low-Dose Computed 
Tomography
Could It be Applied for 
Secondary Prevention 
in Patients Undergoing 
Resection for Lung Cancer?
To the Editor:
In the January issue of Journal of 
Thoracic Oncology, Field et al.1 reem-
phasize the recently published results 
of the National Lung Screening Trial 
(NLST) regarding the role of low-
dose spiral computed tomography 
(CT) as a screening modality in heavy 
smokers. The Strategic CT Screening 
Advisory Committee is currently 
engaging professional societies to 
focus on delivering clear guidelines 
and recommendations in this regard. 
Notably, NLST showed that primary 
prevention with low-dose CT in heavy 
smokers led to 20% fewer deaths from 
non–small-cell lung cancer (NSCLC) 
when compared with screening via 
old-fashioned chest radiographs.2 
There is no doubt that recent techni-
cal developments have revolutionized 
CT capabilities and, as a result, its 
clinical applications. However, cost-
effectiveness of this screening modal-
ity and the amount of overdiagnosis 
in the NLST remains to be clarified 
before recommending it for general 
practice.1,2 Confounding comorbidi-
ties and practical hurdles may further 
reduce this screening’s efficacy, as 
89% of smokers will never develop 
lung cancer.
Conversely, it is known that 
20% of completely resected Stage I 
NSCLC patients do develop recur-
rent lung cancer, most commonly 
to the thorax and usually within the 
first years postoperatively.3 The recur-
rence rate more than doubles for the 
FIGURE 1. Multiple skin lesions occurring on right lower quadrant of the abdo-
men. Some tumors have undergone self-destruction and fusion.
FIGURE 2. A, Abdominal CT showing multiple skin lesions in the right lower 
quadrant of the abdomen and tumor infiltration to subcutaneous tissue. B, CT after 
six cycles of gemcitabine, revealing significant reductions to tumors. CT, computed 
tomography.
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